UC Berkeley, MIT scientists argue over patent rights to gene-editing tool
Disagreement persists between scientists at UC Berkeley and the Massachusetts Institute of Technology over the disputed patent rights to a gene-editing technology known as CRISPR-Cas9 potentially worth billions of dollars.